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Triterpenoids extracted from Ganoderma lucidum (Leyss. ex Fr.) Karst were separated and
characterized using optimized reversed-phase liquid chromatography with diode array
detection and electrospray ion trap tandem mass spectrometry (HPLC-DAD-ESI-MSn). They
could be classified into five types depending on the fragmentation behavior. All triterpenoids
gave [M – H]– and [2M – H]– ions by electrospray ionization monitored in the negative ion
mode; in addition, compounds of types III and IV gave prominent [M – H – H2O]
– ions and
the unsaturated bond at C-20, 22 would reduce the abundance of [M – H – H2O]
– ion. The key
fragmentation information was cleavage at C- and D-rings despite the predominant losses of
H2O and CO2. Compounds with hydroxyls at C-7 and C-15 would produce a list of b, b – 1,
b – 2, and b – 16 ions attributed to cleavage of D-ring; if the second alcohol at C-15 were
oxidized to ketone, the prominent cleavage would occur at C-ring and produce a group of ions
of a; if C-7 were oxidized to ketone, transference of two hydrogen atoms would occur during
the cleavage of rings and a list of ions about a  2 and/or b  2 would appear instead. The
above fragmentations and regularities in fragmentation pathways were reported for the first
time, and were implemented for the analysis of triterpenoids in G. lucidum. The chloroform
extract was separated on a Zorbax SB-C18 column, eluting with an acetonitrile-0.2% acetic acid
gradient. A total of 32 triterpenoids, including six new ones, were identified or tentatively
characterized based on the tandem mass spectra of the HPLC peaks. (J Am Soc Mass
Spectrom 2007, 18, 927–939) © 2007 American Society for Mass SpectrometryGanoderma lucidum (Leyss. ex Fr.) Karst, a medic-inal fungus called “Lingzhi” in China, is acommonly used Chinese herb and an important
ingredient in traditional Chinese medicine herbal formu-
lations for the prevention and treatment of various types
of diseases, such as cancer, hepatopathy, arthritis, hyper-
tension, neurasthenia, debility, etc. Lingzhi has long been
used as a folk remedy for promotion of health and
longevity in China and other oriental countries. The most
attractive character of this kind of medicinal fungus is its
immunomodulatory and antitumor activities [1–7].
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doi:10.1016/j.jasms.2007.01.012Clearly, the activities of G. lucidum are mainly due to
polysaccharides and/or triterpenoids of the fungus.
Over 130 triterpenoids have been isolated from the
fruiting bodies, cultured mycelia, and spores during the
past two decades [8, 9]. Some of the triterpenoids
showed antiandrogenic [10], antihepatitis B [11], anti-
oxidant [12, 17], antitumor [13, 15], anticomplement
[14], antimicrobial [16], anti-HIV-1 [18], selectively in-
hibit eukaryotic DNA polymerase [19], and angiotensin
converting enzyme-inhibitory activities [20]. Thus, a
valuable and convincing method for characterization of
triterpenoids of G. lucidum is necessary for quality
control of the herbal medicine.
Mass spectrometry is the most selective technique for
the rapid qualitative determination of known com-
pounds as well as the identification of unknown com-
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methods were established for separation and detection
of triterpenoids in G. lucidum [25, 26]. In this study, an
integrated approach consisting of LC/ESI-MS and tan-
dem mass spectrometry (MSn) has been used for the
identification of triterpenoids in G. lucidum extracts. To
the best of our knowledge, we report here for the first
time a comprehensive analysis for the triterpenic acids
occurring in G. lucidum based on MSn technique. Using
ESI-MS, it has been possible to obtain structurally
significant fragmentation ions of triterpenoids. The
present approach could be applied to studies of triter-
penoids in crude extracts of G. lucidum. A total of 32
compounds were identified or tentatively characterized
from the chloroform extract of G. lucidum (Figure 1,
Table 1); six of them are reported for the first time.
Experimental
Chemicals
Ganoderic acid A, B, AM1, C2, D, G, H, J, K, ganoderenic
acid B, and 3-hydroxy-4, 4, 14-trimethyl-7, 11, 15-trioxo-
chol-8-en-24-oic acid were isolated from the fruit bodies of
G. lucidum. All these structureswere fully characterized by
direct comparison of their NMR andMS spectra data with
those reported in the literatures [27–33]. Their purities
were over 95%determined byHPLC/UV analysis. HPLC-
grade acetonitrile (MeCN) (Burdick and Jackson-Honey-
well Intl., Muskegon, MI) and ultra-pure water were used
for all analyses. The chloroform and methanol for sample
preparation and the acetic acid (CH3COOH) used in the
mobile phase were of AR grade, purchased from Beijing
Chemical Corp. (Beijing, China).
Sample Preparation
G. lucidum was obtained from the cultivation base of
Green Valley Pharmaceutical Co. Ltd. (Shanghai,
China). A 2.0 g powder of dried samples was extracted
with 40 mL CHCl3 in an ultrasonic water bath for 20
min. This extraction was repeated twice. The extracted
solution was mixed and filtrated through analytical
filter paper; then the filtered solution was evaporated at
35 °C to dryness in vacuum. The dry extract was
dissolved in 5 mL methanol and filtrated through a 0.45
m membrane filter unit. Then 3 L of each sample
solution was analyzed by HPLC.
Chromatography
The analyses were performed on an Agilent series 1100
HPLC instrument (Agilent, Waldbronn, Germany)
equipped with a quaternary pump, a diode-array de-
tector (DAD), an autosampler, and a column compart-
ment. The sample was separated on a Zorbax SB-C18
column (5 m, 4.6  250 mm; Agilent). The mobile
phase consisted of acetonitrile (CH3CN) and water
containing 0.2% (vol/vol) CH3COOH, with a gradientfrom 30 to 32% CH3CN over the first 40 min, then to
40% in 20 min, and held at 40% CH3CN for another 5
min. The flow rate was 1.0 mL/min, and column
temperature was set at 35 °C. The DAD detector was
monitored at 252 nm, and the on-line UV spectra were
recorded in the range of 190 to 400 nm.
Mass Spectrometry
A Finnigan LCQ Advantage ion trap mass spectrometer
(ThermoFinnigan, San Jose, CA) was connected to the
Agilent 1100 HPLC instrument via an ESI interface. The
LC effluent was introduced into the ESI source in a
post-column splitting ratio of 2:1. Ultrahigh-purity he-
lium (He) was used as the collision gas and high-purity
nitrogen (N2) as the nebulizing gas. The MS detector
was optimized by injecting a 5 L/min flow of triter-
penoid standards (0.1 mg/mL in methanol) to obtain
maximum intensities of [M – H]– ions. The optimized
parameters in the negative ion mode were as follows:
ion spray voltage, 4.0 kV; sheath gas (N2), 40 arbitrary
units; auxiliary gas (N2), 10 units; capillary temperature,
270 °C; capillary voltage, 30 V; tube lens offset volt-
age, 25 V. For full scan MS analysis, the spectra were
recorded in the range of m/z 80 to 1200. A data-
dependent acquisition was set so that the two most
abundant ions in full scan MS would trigger tandem
mass spectrometry (MSn, n  2 to 4). The collision
energy for MSn was adjusted to 41% in LC/MS analysis,
and the isolation width of precursor ions was 3.0 m/z.
Results and Discussion
ESI-MSn Analysis of Pure Standards
ESI-MS spectra in both negative and positive modes were
examined in this study. Negative mode ESI was found to
be sensitive for triterpenic acids. Pure compounds (0.1
mg/mL in MeOH) were injected into the ESI source by
continuous infusion. All triterpenoids gave [M – H]– and
[2M – H]– ions in their negative ion mass spectra. The [M
– H]– were selected for CID fragmentation to produce
MS/MS spectra. The prominent MS/MS ions were se-
lected for further MSn analysis (n  3 to 4). The collision
energy ranged from 30 to 50%.
The compounds could be classified into five groups
according to their chemical structures and fragmenta-
tion patterns. The dominant fragmentation pathways of
the compounds studied are losses of H2O and CO2;
however, the cleavages of C-ring and D-ring, which
produce a, b, c, d, e ions etc. (Figure 1), are characteristic
features. The major fragmentation pathways are given
in Scheme 1.
Fragmentation of Ganoderic Acid A and Ganoderic
Acid C2 (Type I)
When applied to an collision energy of 40%, the [M –
H]– ion at m/z 515 of ganoderic acid A (Figure 2a)
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bond
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1 12-hydroxyganoderic acid C2 A β-OH β-OH α-OH OH − 534
2 Ganoderic acid C2 A β-OH β-OH α-OH H − 518
3 Ganolucidic acid B A β-OH H α-OH H − 502
4 Lucidenic acid N B β-OH β-OH =O H − 460
5 Ganoderic acid C6 A β-OH =O =O β-OH − 530
6 3?-hydroxy-4,4,14-trimethyl-7,11,15-trioxochol-
8-en-24-oic acid 
B β-OH =O =O H − 458
7 Ganoderic acid G A β-OH β-OH =O β-OH − 532
8 Ganoderenic acid B A β-OH β-OH =O H ∆20,22 514
9 Ganoderic acid B A β-OH β-OH =O H − 516
10 Lucidenic acid E B β-OH =O =O β-OAc − 516
11 Ganoderic acid AM1 A β-OH =O =O H − 514
12 Ganoderenic acid K A β-OH β-OH =O β-OAc ∆20,22 572
13 Ganoderic acid K A β-OH β-OH =O β-OAc − 574
14 7,15-dihydroxy-4,4,14-trimethyl-3,11-dioxochol-
8-en-24-oic acid 
B =O OH OH H − 460
15 Elfvingic acid A A =O =O β-OH α-OH ∆20,22 528
16 Ganoderic acid A A =O β-OH α-OH H − 516
17 Ganoderic acid H A β-OH =O =O β-OAc − 572
18 12,15-bis(acetyloxy)-3-hydroxy-7,11,23-trioxo-
lanost-8-en-26-oic acid 
A OH =O OAc OAc − 616
19 Ganolucidic acid A A =O H α-OH H − 500
20 12-hydroxy-3,7,11,15,23-pentaoxo-lanost-8-en-
26-oic acid 
A =O =O =O OH − 528
21 Lucidenic acid A B =O β-OH =O H − 458
22 12-hydroxyganoderic acid D A =O β-OH =O OH − 530
23 Ganoderenic acid D A =O β-OH =O H ∆20,22 512
24 Lucidenic acid F B =O =O =O H − 456
25 Ganoderic acid D A =O β-OH =O H − 514
26 Lucidenic acid D B =O =O =O β-OAc − 514
27 Ganoderic acid F A =O =O =O H − 512
28 12-acetoxyganoderic acid D A =O β-OH =O OAc − 572
29 3-acetylganoderic acid H A β-OAc =O =O β-OAc − 614
30 Ganolucidic acid D C − − − − − 500
31 12-acetoxyganoderic acid F A =O =O =O β-OAc − 570
32 Ganoderic acid J A =O =O α-OH H − 514
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Figure 1. Chemical structures of the triterpenoids identified from Ganoderma lucidum and the
characteristic fragmentation pathways of triterpenic acids.
Table 1. Identification of Triterpenic Acids from the Chloroform Extract of Ganoderma glucidum
No.
Retention
time (min) Assigned identity
UV max
(nm)
[M-H]- and [2M-
H]- m/z HPLC/ESI-MSn m/z (% base peak)
1b 6.74 12-Hydroxyganoderic acid C2 – 533 MS
2[533]: 515(100), 486(20)
MS3[533¡515]: 497(7), 485(100), 467(21), 453(20), 423(10), 303(7)
MS4[533¡515¡485]: 467(100), 423(25), 405(11), 288(11)
2a 14.91 Ganoderic acid C2 258 517,1035 MS
2[517]: 499(100), 438(14), 304(6)
MS3[517¡499]: 481(30), 456(7), 437(100), 407(6), 302(15), 287(17)
MS4[517¡499¡437]: 437(80), 422(16), 407(100)
3 16.63 Ganolucidic acid B – 501 MS2[501]: 483(100), 458(6), 439(49), 421(7), 289(93), 287(31)
4 18.13 Lucidenic acid N 258 459, 919 MS2[459]: 441(100), 423(30), 397(41), 385(52), 331(17), 303(10), 289(56), 288(11), 263(34),
260(11), 249(28), 195(16)
MS3[459¡441]: 441(25), 423(100), 397(41), 263(21), 249(24)
MS4[459¡441¡423]: 408(100)
5 18.50 Ganoderic acid C6 254 529,1059 MS
2[511]: 481(9), 467(100), 438(6)
MS3[511¡467]: 467(33), 451(9), 449(12), 437(100), 424(22), 319(6), 303(19), 301(49)
MS4[511¡467¡437]: 437(100), 419(22)
6a 20.16 3-hydroxy-4,4,14-trimethyl-
7,11,15-trioxochol-8-en-24-
oic acid
– 457, 915 MS2[457]: 439(94), 421(82), 413(76), 397(100), 395(40), 385(52), 383(16), 382(27), 379(6),
338(10), 303(42), 287(9), 249(77), 163(46)
MS3[457¡397]: 382(100)
7a 21.20 Ganoderic acid G 256 531,1063 MS2[513]: 498(11), 469(100), 454(47), 452(33), 437(23), 304(10), 302(21), 266(48)
MS3[513¡469]: 451(31), 290(13), 265(100)
8a 21.27 Ganoderenic acid B 248 513,1027 MS2[495]: 480(19), 452(34), 451(100), 437(13), 331(12)
MS3[495¡451]: 433(29), 407(6), 331(74), 315(9), 303(26), 287(31), 263(100), 249(18),
241(7)
MS4[495¡451¡263]: 247 (100)
9a 23.14 Ganoderic acid B 258 515,1031 MS2[497]: 453(100), 439(8), 304(30), 288(6), 250(13)
MS3[497¡453]: 435(9), 409(6), 287(16), 263(26), 249(100)
10 24.09 Lucidenic acid E – 515,1031 MS2[515]: 473(100)
MS3[515¡473]: 458(10), 455(67), 443(100), 437(15), 429(6), 427(9), 413(13), 411(28),
394(12), 384(10), 370(7), 352(16), 330(23), 304(9), 289(17), 274(6)
MS4[515¡473¡443]: 443(19), 425(100), 400(6), 381(18), 326(13)
11a 24.47 Ganoderic acid AM1 270 513,1027 MS
2[513]: 495(24), 451(100), 436(24)
MS3[513¡451]: 436(100), 249 (1)
MS4[513¡451¡436]: 435(69), 421(100)
12b 26.03 Ganoderenic acid K 250 571 MS2[553]: 538(37), 511(13), 494(8), 467(100), 450(8)
13a 27.38 Ganoderic acid K 256 573,1147 MS2[555]: 513(22), 511(77), 496(29), 470(100), 452(43), 304(13), 303(18), 266(11)
MS3[555¡469]: 469(8), 451(31), 290(53), 265(100)
MS4[555¡469¡265]: 237(100)
14b 28.36 7,15-dihydroxy-4,4,14-
trimethyl-3,11-dioxochol-8-
en–24-oic acid
– 459, 919 MS2[459]: 441(86), 423(7), 415(26), 397(11), 300(69), 299(44), 285(100)
MS3[459¡285]: 285(100), 269(47), 187(7)
15 29.70 Elfvingic acid A 256 527,1055 MS2[509]: 479(8), 465(100), 435(6)
MS3[509¡465]: 465(67), 435(100), 421(7), 317 (1), 301(13), 299(33)
MS4[509¡465¡435]: 435(100), 417(12)
16a 31.84 Ganoderic acid A – 515,1031 MS2[515]: 497(100), 480(9), 454(6), 436(19), 302(9), 301(6)
MS3[515¡497]: 479(47), 435(100), 300(10), 299(8), 285(18)
MS4[515¡497¡435]: 435(100), 420(14), 405(82), 378(6), 365(10)
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Table 1. Continued
No.
Retention
time (min) Assigned identity
UV max
(nm)
[M-H]- and [2M-
H]- m/z HPLC/ESI-MSn m/z (% base peak)
17a 31.91 Ganoderic acid H – 571 MS2[553]: 515(29), 512(100), 510(22), 468(22)
MS3[553¡511]: 481(9), 467(100)
MS4[553¡511¡467]: 467(37), 437(100), 423(8), 301(43)
18b 33.55 12,15-bis(acetyloxy)-3-
hydroxy-7,11,23-trioxo-
lanost-8-en-26-oic acid
– 615 MS2[597]: 553(100), 511(21)
MS3[597¡553]: 523(7), 511(67), 509(100), 493(66), 467(25), 449(23)
MS4[597¡553¡509]: 479(9), 467(95), 449(100)
19 34.61 Ganolucidic acid A 220,258 499, 999 MS2[499]: 481(100), 455(7), 437(77), 287(57), 285(88), 233(15)
MS3[499¡481]: 437(100), 285(59)
20 36.75 12-hydroxy-3,7,11,15,23-
pentaoxo-lanost-8-en-26-
oic acid
– 527 MS2[509]: 465(100)
MS3[509¡465]: 465(56), 435(100), 317 (1), 301 (17), 299(40)
MS4[509¡465¡435]: 435(100)
21 39.12 Lucidenic acid A 256 457, 915 MS2[457]: 442(14), 439(100), 421(25), 395(43), 383(24), 329(7), 323(6), 287(56), 285(12),
261(34), 258(13), 247(7), 209(14), 193(15), 149(15)
MS3[457¡439]: 424(59), 421(71), 323(36), 287(28), 261(100)
22 39.77 12-hydroxyganoderic acid D 256 529,1059 MS2[511]: 496(24), 493(24), 467(100), 452(69), 449(70), 434(30), 317(10), 301(14), 300(6),
299(20), 263(69)
MS3[511¡467]: 449(22), 288(51), 263(100)
23 42.92 Ganoderenic acid D 246 511,1023 MS2[493]: 479(8), 478(25), 450(34), 449(100), 435(18), 329(10), 286(7)
MS3[493¡449]: 431(8), 405(27), 335(7), 329(53), 301(15), 285(100), 283(9), 261(99),
247(12), 172(9), 149(11)
24 45.92 Lucidenic acid F 250 455, 911 MS2[455]: 437(84), 425(14), 419(56), 411(53), 395(100), 393(22), 383(35), 380(39), 377(10),
339(9), 301(55), 247(52), 245(36), 209(12), 207(7), 163(32), 149(9)
MS3[455¡395]: 380(100)
25a 47.20 Ganoderic acid D 256 513,1027 MS2[495]: 451(100), 437(15), 301(31), 286(10), 284(11), 247(11)
MS3[495¡451]: 436(6), 433(11), 407(28), 285(56), 261(10), 247(100), 149(68)
MS4[495¡451¡247]: 149(100)
26 49.94 Lucidenic acid D 252 513,1027 MS2[513]: 471(100)
MS3[513¡471]: 456(14), 453(57), 441(100), 438(7), 435(12), 428(8), 411(7), 409(20),
391(10), 349(9), 328(23), 301(8), 300(10), 287(16), 272(9)
MS4[513¡471¡441]: 441(21), 423(100), 397(10), 379(19), 340(20), 324(13)
27 51.50 Ganoderic acid F 260 511,1023 MS2[511]: 493(39), 449(100), 435(17)
MS3[511¡449]: 434(100), 431(7)
MS4[511¡449¡434]: 433(100), 419(97)
28b 52.60 12-acetoxyganoderic acid D 256 571,1143 MS2[553]: 538(6), 511(51), 509(77), 494(46), 476(10), 467(100), 450(75), 302(16), 301(21),
263(12)
MS3[553¡467]: 468(19), 449(33), 407(8), 288(56), 263(100)
29b 53.06 3-acetylganoderic acid H – 613 MS2[595]: 553(100), 552(21), 510(17)
MS3[595¡553]: 523(8), 509(100)
MS4[595¡553¡509]: 509(64), 479(100), 465(14), 449(52), 345(13), 343(41)
30 54.47 Ganolucidic acid D 258 499, 999 MS2[499]: 481(60), 437(100), 287(15), 285(45)
MS3[499¡437]: 287(6), 285(100)
MS4[499¡437¡285]: 285(100), 269(66), 213(8), 187(8)
31 57.68 12-acetoxyganoderic acid F 256 569,1139 MS2[551]: 509(100), 508(14), 466(15)
MS3[551¡509]: 479(10), 465(100), 436(6)
MS4[551¡509¡465]: 465(47), 449(12), 447(12), 435(100), 422(9), 317 (1), 301(13), 299(38)
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932 YANG ET AL. J Am Soc Mass Spectrom 2007, 18, 927–939produced a prominent ion at m/z 497 by eliminating a
molecule of H2O (m 18). Them/z 497 ion was further
subjected to MS3 analysis to produce signals at m/z 479
and 435, formed by the sequential losses of H2O and
carbon dioxide (CO2, m  44) through a rearrange-
ment process at the side chain, as suggested in Scheme
1. The m/z ion 435 then underwent successive losses of
CH3 (m  15) to generate an ion at m/z 405. The above
product ions were the dominant fragments of ganoderic
acid A; moreover, some minor signals at m/z 285 (b –
16), 301 (b), 300 (b – 1), and 299 (b – 2) were also
observed in MSn (n  2 to 3) spectra, especially in the
MS3 spectrum (Figure 3). We assumed that the fragmen-
tation should result from cleavage of the D-ring (Figure
1), and this provided characteristic information for
compounds with skeletons such as that of ganoderic
acid A. The fragmentation pathway is depicted in
Scheme 1.
Ganoderic acid C2 gave similar ESI-MS
n (n  1 to 4)
spectra to those of ganoderic acid A, except that the
corresponding ions were heavier by 2 Da, which re-
sulted from the difference of the group at C-3. Hence, it
could be concluded that different groups at C-3 do not
change the main fragmentation pathway of the com-
pounds investigated.
Fragmentation of Ganoderic Acid AM1
and Ganoderic Acid J (Type II)
Ganoderic acid AM1 gave the [M – H]
– ion at m/z 513,
which produced ions at m/z 495 and 451 in the MS/MS
spectrum, originating from neutral loss of H2O and CO2
similar to the results of ganoderic acid A; but ions
involving cleavage of the rings were hardly observed;
the very minor a  2 ion at m/z 249 indicated a
characteristic rearrangement in the process of cleavage
of the rings for the structures with 7-carbonyl (see
Scheme 1). MS3 and MS4 spectra of ganoderic acid AM1
yielded abundant product ions at m/z 436 and 421
respectively, through loss of CH3 (m  15).
The fragmentation behavior of ganoderic acid AM1
could be applied to ganoderic acid J. The [M – H]– ion
at m/z 513 gave a prominent product ion at m/z 451; the
MS3 spectrum of the m/z 451 ion was somewhat differ-
ent from that of ganoderic acid AM1; it gave two
abundant ions at m/z 436 and 421 (Figure 4). We
suggested that this might be due to the different sub-
stitute at C-15. In such a case, loss of a molecule of H2O
could be observed in the MS4 spectrum.
Fragmentation of Ganoderic Acid B, D, G, K,
and Ganoderenic Acid B (Type III)
The fragmentation behavior of ganoderic acid B were
very different from those of compounds of types I and
II. In its full scan MS spectrum, the prominent signal
was not the [M – H]– ion at m/z 515 but the [M – H –
H2O]
– ion at m/z 497 (Figure 2b), resulting from aTa N
o
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Scheme 1. We assumed that this was the characteristic
fragmentation feature for structures with 15-hydroxy-
7-oxo groups. The m/z 497 ion was then subjected to
MS/MS analysis and produced a prominent ion at m/z
453, formed by loss of a molecule of CO2 (m  44).
Figure 4d shows the MS3 spectrum of the m/z 453 ion;
the most prominent product ion was at m/z 249 (a),
followed by the a  CH2 ion at m/z 263 along with b –
H – CH3 ion atm/z 287, corresponding to rearrangement
and cleavage of the C- and D-rings, respectively (see
Scheme 1).
All issues discussed above for ganoderic acid B could
apply here for other compounds of type III. Ganoderic
acid D had almost identical ESI-MSn (n 1 to 4) spectra
with those of ganoderic acid B, except that the corre-
sponding ions were lighter by two mass units, resulting
from the different substitution at C-3. Ganoderic acid G
was a monohydroxylated derivative at C-12 of gano-
deric acid B and, thus, all its corresponding ions (a ion
at m/z 265, b ion at m/z 319) were heavier by 16 Da than
those of ganoderic acid B. Ganoderic acid K was a
acetylated derivative at C-12 of ganoderic acid G and its
[M – H – H2O]
– ion at m/z 555 yielded an ion in the
MS/MS spectrum at m/z 513, originating from a neutral
loss of 42 Da (CH2  CO). We assumed that this
reaction involved the elimination of the acetyl at C-12.
The obtained ion then showed the same fragmentation
patterns as those of ganoderic acid G. Some character-
istic signals were shown in Table 2.
Figure 2. Full scan MS spectra for ganoderic acid A (a), gano-
deric acid B (b), and ganoderenic acid B (c).The mass spectrum of ganoderenic acid B was some-what different from that of ganoderic acid B. Its full
scan MS spectrum gave both [M – H]– ion (m/z 513) and
[M – H – H2O]
– ion (m/z 495) in abundant signals
(Figure  2c). We suggested that this character could be
applied for all other ganoderenic acids. The [M – H –
H2O]
– ion at m/z 495 showed similar fragmentation
patterns to those of ganoderic acid B, but the abun-
dances of some ions were very different. The a  CH2
ion (m/z 263) was a base peak in the MS3 spectrum,
followed by e ion at m/z 331 (see Figure 1 and Scheme
1), along with b – H – CH3 ion atm/z 287; the a ion atm/z
249 was less abundant on the contrary to that of
ganoderic acid B.
Fragmentation of Ganoderic Acid H (Type IV)
Ganoderic acid H was an acetoxylated derivative at
C-12 of ganoderic acid AM1, but its fragmentation
behavior was somewhat different from those of gano-
deric acid AM1. The most prominent ion in its full scan
mass spectrum was the [M – H – H2O]
– ion at m/z 553
like that of ganoderic acid K. Neutral losses of CH2 
CO (m  42, m/z 553¡511), and CO2 (m  44, m/z
511¡467) were observed in the MS2 and MS3 spectra,
respectively. The obtained m/z 467 ion then gave abun-
dant signals at m/z 301 and 303 in the MS4 spectrum
along with the base peak at m/z 437. We assumed that
the two ions should be b 2 – H2O and b 2 – H – CH3
ions (Figure 5c), involving the transfer of two hydrogen
atoms from part d to part b in the process of cleavage of
the D-ring (Scheme 1); this could be the characteristic
feature for structures with 12-hydroxy-7-oxo groups.
Figure 3. ESI-MS spectra for ganoderic acid A: (a) MS/MS
spectrum of [M – H]– ion at m/z 515 ; (b) MS3 spectrum of m/z 497
(515¡497); (c) MS4 spectrum of m/z 435 (515¡497¡435); (d) the
box zoomed in for b, b – 1, b – 2 and, b – 16 ions.
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7, 11, 15-Trioxochol-8-en-24-oic Acid (Type V)
The structure of this type of compound has a skeleton of
lanostane containing 27 carbon atoms and is called
lucidenic acid. Part of the structure is similar to that of
Figure 4. ESI-MS spectra for ganoderic acids: M
(a) and ganoderic acid J (b); MS/MS spectrum
ganoderic acid B.
Table 2. Characteristic ESI-MS spectral information for Type III
No.
Full scan (m/z, %)
a[M – H]– [M – H – H2O]
–
7 531 (7) 513 (100) 26
8 513 (100) 495 (80) 24
9 515 (25) 497 (100) 24
12 571 (86) 553 (100) 26
13 573 (15) 555 (100) 26
22 529 (7) 511 (100) 26
23 511 (80) 493 (100) 24
25 513 (20) 495 (100) 24
28 571 (1) 553 (100) 26
Figure 5. ESI-MS spectra for ganoderic acid H
553; (b) MS3 spectrum of m/z 511 (553¡511); (c) M
spectrum of [M – H]– ion at m/z 457 for 3-hydr
acid.ganoderic acid except the side chain at C-17. Thus, some
characteristic fragmentation features of ganoderic acid
could be applied for lucidenic acid.
Figure 5d shows the MS/MS spectrum of the [M –
H]– ion at m/z 457 for 3-hydroxy-4, 4, 14-trimethyl-7,
pectra for ion at m/z 451 of ganoderic acid AM1
/z 497 (c) and MS3 spectrum at m/z 453 (d) of
rpenoids
a  14 b b – 16 b – 29
319 303 290
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261 301 285
301 288
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ion was m/z 397, originating from loss of a molecule
of acetic acid (CH3COOH, m  60) through the -
cleavage of the carboxy group. In addition, [M – H –
H2O]
– (m/z 439), [M – H – 2H2O]
– (m/z 421), and [M – H
– CO2]
– (m/z 413) ions were also observed. The appear-
ance of a  2 (m/z 249) and b  2 (m/z 303) ions
demonstrated characteristic fragmentation feature for
structures with 7-carbonyl.
HPLC-DAD-ESI-MSn Analysis of the Crude
Extract of Ganoderma lucidum
Figure 6 shows the HPLC-UV and TIC profiles of the
extract of Ganoderma lucidum. To obtain optimal ex-
traction efficiency and good separation, we opti-
mized the extraction and chromatographic conditions
[34]. Chloroform, methanol, and chloroform-metha-
nol solutions were attempted as the extraction sol-
vent. At last, chloroform was chosen as the extraction
solvent since the triterpenoids could not only effi-
ciently be extracted but also well resolved from
background. Ultrasonic extraction was compared
with refluxing. It was found that both extraction
methods have the similar extraction efficiency but
ultrasonic extraction was simpler, hence the ultra-
sonic bath extraction was chosen as the preferred
method.
Different mobile phase compositions were optimized
and acetic acid was added in the mobile phase to obtain
desired separation and acceptable tailing factor. As a
result, acetonitrile and water containing 0.2% acetic acid
Figure 6. HPLC-DAD-ESI-MSn analysis of the
chromatogram monitored at 252 nm. (b) LC-negwas chosen as the eluting solvent system. The UVdetector was monitored at 252 nm to make sure that all
triterpenoids gave good responses.
A total of 32 triterpenoids were characterized from
the chloroform extract of G. lucidum (Table 1), and 11
of them were unambiguously identified by compar-
ing their retention times and mass spectra with those
of reference standards. For unknown peaks, the struc-
tures were tentatively established on the base of their
ESI-MS and MSn (n  2 to 4) spectra, according to the
general fragmentation rules of triterpenoids summa-
rized above.
Identification of Type I Triterpenoids
In addition to ganoderic acid A (tR  31.84 min, 16) and
C2 (tR  14.91 min, 2), another peak at 6.74 min (Table
1, Compound 1) was plausibly identified. A group of
signals at m/z 319 (b), 318 (b – 1), 317 (b – 2), and 303 (b
– 16) demonstrated the structure of type I triterpenoid.
The loss of 30 Da in the MS3 spectrum was attributed to
the elimination of a molecule of formaldehyde (HCHO)
at C-12 (Scheme 2). Thus, Compound 1 was tentatively
l3 extract of Ganoderma lucidum. (a) HPLC-UV
ion ESI-MS total ion current (TIC) profile.
Scheme 2. Proposed fragmentation mechanism for the neutralCHCloss of 30 Da from ion at m/z 515 of Compound 1.
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reported for the first time.
Identification of Type II Triterpenoids
Ganoderic acid AM1 (tR  24.47 min, 11) and ganoderic
acid J (tR  59.26 min, 32) were identified by compari-
son with the standards. Compound 27 (tR  51.50 min)
gave the [M – H]– ion at m/z 511, which gave almost
identical MSn (n  2 to 4) spectra to those of ganoderic
acid AM1, except that the corresponding ions were
lighter by two mass units. Thus, it is presumed to be a
3-oxo derivative, and was assigned as ganoderic acid F,
just bearing a different substitute at C-3 compared with
ganoderic acid AM1.
Identification of Type III Triterpenoids
Ganoderic acid B (tR  23.14 min, 9), D (tR  47.20 min,
25), G (tR  21.20 min, 7), K (tR  26.03 min, 12), and
ganoderenic acid B (tR  21.27 min, 8) were identified
by comparison with the standards. According to the
data shown in Table 2, Compounds 12 (tR  26.03 min),
22 (tR  39.77 min), 23 (tR  42.92 min), and 28 (tR 
52.60 min) could also be easily characterized. It was
clear that Compounds 12 and 23 were ganoderenic
acids (20, 22-double-bond) because their [M – H]– ions
had similar abundance (80%) to that of [M – H –
H2O]
– ions. Thus, Compound 12 must be a C-20, 22
unsaturated derivative of Compound 13 (ganoderic
acid K), and hence assigned as ganoderenic acid K,
which is reported for the first time. Similarly, Com-
pound 23 was tentatively characterized as ganoderenic
acid D.
Compounds 22 and 28 showed very similar ESI-MSn
spectra to those of Compounds 7 and 13, respectively,
except that the according ions were lighter by 2 Da,
indicating the different substitution at C-3. Therefore,
Compound 22 was assigned as 12-hydroxyganoderic
acid D, and Compound 28 was tentatively identified as
12-acetoxyganoderic acid D.
Identification of Type IV Triterpenoids
Table 3. Characteristic ESI-MS Spectral Information for Type
IV Triterpenoids
No.
Full scan (m/z, %)
b b – 16 b – 18[M – H]– [M – H – H2O]
–
5 529 (11) 511 (100) 319 303 301
15 527 (91) 509 (100) 317 301 299
17 571 (17) 553 (100) 319 303 301
18 615 (15) 597 (100) – – –
20 527 (8) 509 (100) 317 301 299
29 613 (56) 595 (100) 361 345 343
31 569 (33) 551 (100) 317 301 299Table 3 shows the characteristic ions of type IV triter-penoids characterized from extract of G. lucidum. These
constituents have the same structural fragment bearing
a hydroxyl (acetoxy) at C-12 and a keto group at C-7.
Compound 17 (tR  31.91 min) was unambiguously
identified as ganoderic acid H by comparison with the
standard. Obviously, the peak at 18.50 min (5) gave
identical b, b – 16, and b – 18 ions to those of ganoderic
acid H. Thus, it was assumed to be a deacetylated
derivative and assigned as the known compound gano-
deric acid C6.
Compound 31 (tR  57.68 min) should be an acety-
lated derivative of Compound 20 (tR 36.75 min). Their
fragmentation behaviors were very similar to those of
Compounds 17 and 5, respectively, except that the
corresponding ions were lighter by 2 Da. We assumed
that they might be the derivatives of Compound 17 and
5 by oxidizing the secondary alcohol at C-3. Thus,
Compound 20 was assigned as 12-hydroxy-3, 7, 11, 15,
23-pentaoxo-lanost-8-en-26-oic acid, and Compound 31
was tentatively characterized as 12-acetoxyganoderic
acid F. Similarly, Compound 29 was plausibly charac-
terized as the new compound named 3-acetylganoderic
acid H.
The peak at 29.70 min (15) was an isomer of 20 and
showed the characteristics of ganoderenic acid ([M – H]–,
m/z 527 (91%); [M – H – H2O]
–,m/z 509 (100%)), indicating
one of the carbonyl was hydrogenized when compared
with 20. The same b, b – 16, and b – 18 ions demonstrated
identical structure of A-, B-, and C-rings to those of 20;
therefore it was suggested that the carbonyl at D-ring
should be hydrogenized. Thus, Compound 15 was tenta-
tively identified as elfvingic acid A, a known compound
isolated from Elfvingia applanata [35].
The ESI-MS spectra of Compound 18 (tR  33.55
min) were somewhat different from other type IV
triterpenoids (Table 3). But there was no doubt that the
skeleton was still similar and there were two acetoxys in
the structure; one was presumably attached at C-12.
Since no signals for a or b ion were observed, another
acetoxyl group should not be attached at C-3 but C-15.
Hence, the peak was tentatively characterized as 12,
15-bis(acetoxy)-3-hydroxyl-7, 11, 23-trioxo-lanost-8-en-26-
oic acid, which is a new compound.
Identification of Type V Triterpenoids
Compounds of this group have a C27 lanostane skele-
ton. The peak at 20.16 min (6) was identified as 3-
hydroxy-4, 4, 14-trimethyl-7, 11, 15-trioxochol-8-en-24-
oic acid by comparison with the standard. The ESI-MS
spectrum of Compound 24 (tR  45.92 min) gave [M –
H]– ion at m/z 455, which was subjected to MS/MS
analysis and showed very similar fragmentation path-
way to that of 6 (Table 4), and the corresponding ions
were lighter by two mass units. It was presumed to be
an oxidized derivative of 6 at C-3 and, hence, assigned
as lucidenic acid F.
The peak at 39.12 min (21) was an isomer of 6. The
ESI-MS/MS spectrum gave abundant a (m/z 247), a 14
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were somewhat similar to those of type III triterpenoids
discussed above. We assumed that there should be a
hydroxyl at C-7 and the C-15 should be a carbonyl, just
like those of ganoderic acid D. Thus, Compound 21was
tentatively characterized as lucidenic acid A. Similarly,
Compound 4 (tR 18.13 min) was assigned as lucidenic
acid N.
Compounds 10 (tR  24.09 min) and 26 (tR  48.72
min) were another couple of derivates, which just
possessed the different substitutes at C-3. Therefore,
they showed very similar fragmentation behaviors. The
[M – H]– ion at m/z 513 of 26 produced the prominent
ion at m/z 471 in the MS/MS spectrum. The obtained
ion was subjected to MS3 fragmentation, in which
abundant ions at m/z 287 (b  2 – HCHO), 301 (b  2 –
CH4), and 328 (e – 17) were observed along with the
base peak at m/z 441 ([M – H – 42 – HCHO]–). The listed
ions on b  2 indicated that C-7 of 26 was oxidized to
be a carbonyl. Moreover, according to the [M – H]– ion,
26might be an acetoxylated derivative of lucidenic acid
F (24). Thus, Compound 26was tentatively identified as
lucidenic acid D. Similarly, Compound 10 was plausi-
bly characterized as lucidenic acid E.
Compound 14 (tR  24.09 min) was an isomer of
lucidenic acid N (4). Its ESI-MS/MS spectrum gave a list
of abundant ions at m/z 301 (b), 300 (b – 1), 299 (b – 2),
and 285 (b – 16), which were obviously the character-
istic ions of ganoderic acid A. Thus, there should be
hydroxyls attached at C-7 and C-15. Hence, Compound
14 was tentatively identified as 7, 15- dihydroxy-4, 4,
14-trimethyl-3, 11-dioxochol-8-en-24-oic acid, a com-
pound reported for the first time.
Identification of Other Compounds
Compounds 3 (tR  16.63 min), 19 (tR  34.61 min), and
29 (tR  54.47 min) gave very similar ESI-MS/MS
spectra. The [M – H]– ion of Compound 3 was at m/z
501, which was 16 Da lighter than that of ganoderic acid
C2 (Table 5). The base peak in its MS/MS spectrum was
[M – H – H2O]
– ion (m/z 483), and the [M – H – H2O –
CO2]
– ion (m/z 439) was abundant. Thus, this compound
appeared to be a dehydroxylated derivative of gano-
Table 4. Characteristic ESI-MS Spectral Information for Type V
No. [M – H – H2O]
– a
4 441 (100) 249
21 439 (100) 247
No. [M – H – 60]– a  2
6 397 (100) 249
24 395 (100) 247
No. [M – H – 42 – 30]– b  2 – HCHO
10 443 (100) 289
26 441 (100) 287
No. [M – H – H2O]
– b
14 441 301deric acid C2. The known compound ganolucidic acid Bcould match this information; therefore, its structure
was plausibly characterized and the ions at m/z 287 and
289 were presumed to be b and b  2, respectively.
Similarly, Compound 19 was tentatively characterized
as ganolucidic acid A.
Compound 29 was an isomer of 19. [M – H – H2O]
–
(m/z 481), [M – H – H2O – CO2]
– (m/z 437), b (m/z 285),
and b  2 (m/z 287) ions were observed in its MS/MS
spectrum. Interestingly, [M – H – H2O – CO2]
– ion was
the base peak. We assumed it might be ganolucidic acid
D, which had a different side chain at C-17 compared
with ganolucidic acid A.
Conclusions
In this study, the fragmentation behavior of triterpe-
noids, which shared the same core triterpene structure
as C30 or C27 lanostane, in electrospray ion trap mass
spectrometer was studied. The predominant fragmen-
tation pathways were losses of H2O and CO2, but their
characteristic behaviors were cleavage of C- and D-
rings. Different substitution at C-7, 12, 15 resulted in
different fragmentation and the double-bond at C-20, 22
would also affect the behaviors of mass spectra.
Using HPLC-DAD-ESI-MS and MSn (n  2 to 4), we
have demonstrated the assignment of 26 known triter-
penoids along with six previously unidentified com-
pounds of Ganoderma lucidum. For analysis of triterpe-
noids in crude extract, we recommended the initial
application of negative ion ESI-MS to obtain the molec-
ular mass information for the components via the [M –
H]– ions, and to determine the structural information by
acquiring MSn spectra. The observed [2M – H]– ions
were found very useful for peak confirmation. Con-
struction of a library containing MSn spectra for known
triterpenoids would greatly facilitate the identification
rpenoids
a  14 b b – 14
263 303 289
261 301 287
b  2
303
301
b  2 – CH4 e – OH
303 330
301 328
b – 1 b – 2 b – 16
300 299 285
Table 5. Characteristic ESI-MS Spectral Information
for Compounds 3, 19, and 30
No. [M – H – H2O]
– [M – H – H2O – CO2]
– b b  2
3 483 (100) 439 (49) 287 289
19 481 (100) 437 (77) 285 287Trite30 481 (60) 437 (100) 285 287
939J Am Soc Mass Spectrom 2007, 18, 927–939 TRITERPENOIDS IN GANODERMA LUCIDUM USING HPLC-ESIof these compounds in real samples and would permit
even more complete fingerprinting of triterpenoids that
arise from species differences of different Ganoderma
extracts.
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